Home Metabolism phosphatase inhibitor GDC-1971

research use only

GDC-1971 phosphatase inhibitor

Cat.No.E1191

GDC-1971 (compound 199) is a SHP2 inhibitor.
GDC-1971 phosphatase inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 454.54

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: E119101 DMSO]91 mg/mL]false]Ethanol]91 mg/mL]false]Water]Insoluble]false Purity: 99.51%
99.51

Chemical Information, Storage & Stability

Molecular Weight 454.54 Formula

C25H26N8O

 Storage (From the date of receipt) 3 years -20°C powder
CAS No. 2377352-49-1 -- Storage of Stock Solutions

Synonyms compound 199 Smiles NC1C2=CC=CC=C2OC13CCN(CC3)C4=CN=C5C(=N4)[NH]N=C5N6CCCC7=NC=CC=C67

Solubility

In vitro
Batch:

DMSO : 91 mg/mL (200.2 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 91 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
SHP2 [1]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05954871 Recruiting
Colorectal Cancer|Non-Small Cell Lung Cancer
Genentech Inc.
 January 8 2024 Phase 1
NCT05487235 Recruiting
Advanced Solid Tumors|Metastatic Solid Tumors
Genentech Inc.
 August 17 2022 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.